Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

Introduction Non-alcoholic fatty liver disease (NAFLD) pathogenesis involves abnormal metabolism of cholesterol and hepatic accumulation of toxic free-cholesterol. Elobixibat (EXB) inhibits the ileal bile acid (BA) transporter. EXB and cholestyramine (CTM) facilitate the removal of free cholesterol...

Full description

Saved in:
Bibliographic Details
Main Authors: Atsushi Nakajima, Takeharu Yamanaka, Koji Yamamoto, Yasushi Honda, Kento Imajo, Masato Yoneda, Yuji Ogawa, Takaomi Kessoku, Takashi Kobayashi, Anna Ozaki, Satoru Saito, Michihiro Iwaki, Yusuke Saigusa, Haruki Usuda, Koichiro Wada
Format: Article
Language:English
Published: BMJ Publishing Group 2020-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/9/e037961.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/10/9/e037961.full

Similar Items